Erowid
 
 
Plants - Drugs Mind - Spirit Freedom - Law Arts - Culture Library  
Review Erowid at GreatNonprofits.org
Help us be a 2021 "Top Rated Nonprofit", and spread accurate info
about psychoactive drugs, health, culture, & policies.
("Share Your Story" link. Needs quick account creation but doesn't verify contact info)
DEA Federal Register Entry
U.S. Federal register
Date="07/19/94" Citation="59 FR 36785" Group="legal" Type="NOTICE" Department="DEPARTMENT OF JUSTICE" Agency="DRUG ENFORCEMENT ADMINISTRATION" Subject="Proposed 1994 Aggregate Production Quota for a Schedule I Controlled S ubstance"
------------------------------------------------------------ Proposed 1994 Aggregate Production Quota for a Schedule I Controlled Substance AGENCY: Drug Enforcement Administration. ACTION: Notice of a proposed 1994 aggregate production quota.
------------------------------------------------------------ Proposed 1994 Aggregate Production Quota for a Schedule I Controlled Substance AGENCY: Drug Enforcement Administration. ACTION: Notice of a proposed 1994 aggregate production quota. + ------------------------------------------------------------ SUMMARY: This notice proposed a 1994 aggregate production quota for 3,4-methylenedioxy-N-ethylamphetamine (MDEA), a controlled substance in Schedule I of the Controlled Substances Act (CSA). DATES: Comments or objections must be received on or before August 18, 1994. ADDRESSES: Send comments or objections to the Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn: DEA Federal Register Representative/CCR. FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183. SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for controlled substances in Schedules I and II each year. This responsibility has been delegated to the Administrator of the DEA pursuant to sec 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator pursuant to 59 FR 23637 (May 6, 1994). A company submitted an application for a manufacturing quota for 3,4-methylenedioxy-N-ethylamphetamine, a Schedule I controlled substance. Based on the review of this application and other information available to the DEA, the Deputy Administrator of the DEA, under the authority vested in the Attorney General by Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator by sec 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to 59 FR 23637 (May 6, 1994), hereby proposes the 1994 aggregate production quota for the following controlled substance, expressed in grams of anhydrous base, be established as follows: --------------------------------------------------------------+--------------- | Proposed | 1994 Basic class | aggregate | production | quota | (grams) --------------------------------------------------------------+--------------- | 3,4-Methylenedioxy-N-ethylamphetamine ....................... | 5 --------------------------------------------------------------+--------------- All interested persons are invited to submit comments or objections, in writing, regarding this proposal. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief. In the event that comments or objections to this proposal raise one or more issues which the Administrator finds warrant a hearing, the Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing. The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in the Executive Order 12612 and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities within the meaning of and intent of the Regulatory Flexibility Act, 5 U.S.C., 601, et seq. The establishment of annual aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis. Dated: July 13, 1994. Stephen H. Greene, Deputy Administrator. [FR Doc. 94-17419 Filed 7-18-94; 8:45 am] BILLING CODE 4410-09-M ------------------------------------------------------ The Contents entry for this article reads as follows: Schedules of controlled substances; production quotas: Schedule I- 1994 proposed aggregate, 36785
.